Aerospace Contractor Pays $1.5 Million to Settle False Claims Allegations Amid Broader Corporate Fraud Crackdown

Teledyne RISI Inc., also known as Teledyne Electronic Safety Products, has agreed to pay $1.5 million to resolve allegations that it violated the False Claims Act by supplying non-conforming aircraft ejection seat components to the U.S. Navy, the Department of Justice announced last week.

According to federal investigators, the aerospace and defense contractor knowingly submitted false claims to the military between November 2011 and June 2012 by providing components that failed to meet Navy-approved specifications. The parts, sourced from a third-party broker, were installed in various military aircraft, potentially compromising pilot safety.

The settlement highlights the Justice Department’s continued focus on procurement fraud in the defense sector, where non-compliant parts can have serious safety implications. The aerospace components industry has faced increased scrutiny in recent years as military branches seek to ensure the integrity of critical safety equipment.

In an unusual move that reflects recent DOJ policy shifts toward cooperative corporate defendants, prosecutors formally acknowledged Teledyne’s substantial cooperation during the investigation. The company received credit under the Justice Manual for identifying involved personnel, facilitating witness interviews, preserving and sharing relevant documents, disclosing findings from its internal investigation, and agreeing to toll applicable statutes of limitation.

The case represents part of a broader enforcement pattern targeting quality control issues in defense contracting, where the stakes include not only financial damages but potential risks to military personnel.

In a separate but equally significant enforcement action, the healthcare technology sector saw one of its harshest sentences in recent memory when Gary Cox, former CEO of Power Mobility Doctor Rx, LLC (DMERx), received a 15-year prison term for orchestrating a massive fraud scheme that targeted Medicare and other federal healthcare programs.

Cox was ordered to pay over $452 million in restitution after being convicted of conspiracy to commit healthcare fraud and wire fraud, multiple counts of healthcare fraud, conspiracy to pay and receive kickbacks, and conspiracy to defraud the United States.

Federal prosecutors demonstrated that Cox and his associates employed misleading advertising and offshore call centers to collect Medicare beneficiary information and arrange for medically unnecessary orthotic braces, pain creams, and other medical items. Through DMERx’s internet platform, the group generated fraudulent doctors’ orders falsely indicating physician examinations had occurred.

The government’s case revealed that telemedicine companies paid doctors to sign orders without proper patient examinations or medical necessity determinations, often after only cursory phone calls or no contact whatsoever with Medicare beneficiaries. Cox facilitated illegal kickbacks between various healthcare entities while concealing the scheme through sham contracts and carefully worded documentation designed to avoid triggering Medicare audits.

The fraud scheme’s scope was remarkable even by healthcare fraud standards, resulting in more than $1 billion in fraudulent claims submitted to Medicare and other insurers, with actual payments exceeding $360 million.

Meanwhile, the financial sector faces its own high-profile fraud case as six individuals were charged last month in connection with an alleged $41 million insider trading and market manipulation scheme targeting healthcare and biopharmaceutical companies.

Federal prosecutors charged Muhammad Saad Shoukat, Muhammad Arham Shoukat, Muhammad Shahwaiz Shoukat, Daniyal Khan, Izunna Okonkwo, and Gyunho Justin Kim for their alleged roles in a complex securities fraud operation spanning from June 2020 to February 2024.

According to court documents, Kim, who worked at an investment bank specializing in healthcare mergers and acquisitions, allegedly obtained material non-public information about at least nine pending transactions and illegally tipped Saad Shoukat. This information was then allegedly shared among the group, who traded on the privileged information for substantial profits.

Beyond the insider trading allegations, the defendants allegedly manipulated stock prices for Olema Pharmaceuticals by purchasing shares, accessing confidential data about an underperforming breast cancer drug, then falsifying and disseminating that data to artificially inflate the company’s stock price before selling their holdings.

In a particularly brazen alleged scheme, the group reportedly created a fake company website and published a sham press release announcing a non-existent merger involving Opiant Pharmaceuticals, temporarily driving up the stock price by approximately 29% before selling shares for profit.

The three enforcement actions highlight the Justice Department’s continued focus on corporate fraud across multiple sectors, with particular emphasis on cases involving public health, safety, or market integrity.